Sichuan Biokin Pharmaceutical Co: Q3 earnings rebounded, while 9M losses and R&D-driven cash outflow remained substantialQuartr·Oct 30, 2026 at 11:07 AM02615688506+4.40%
Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study | BMY Stock NewsStockTitan·Oct 25, 2026 at 11:30 PMBMY-2.92%02615
Sa Sa International Q1 Revenue Jumps 24% as Hong Kong Equities Show Mixed RecoveryGlobal Report·Aug 7, 2026 at 09:18 AM03788-3.71%02166+6.18%
SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell CarcinomaUnusual Whales·Jul 17, 2026 at 12:27 PM688506+4.40%02615
Mobile’s Cash Flow Surges 128% as Gome Resorts to Share Issuance for Debt SurvivalGlobal Report·Jul 7, 2026 at 10:38 AM00951-1.63%00788-1.04%
15:07 ETSystImmune Announces First Approval of Iza-bren for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma in Chinaprnewswire·Jun 22, 2026 at 07:09 PM688506+4.40%02615
Bristol Myers says ADC licensed from China hits mark in aggressive breast cancerbiopharmadive·Feb 27, 2026 at 01:55 AM688506+4.40%02615
Biokin Pharmaceutical T-Bren (HER2 ADC) demonstrates best-in-class potential, revealing efficacy data for treated HER2 mutated NSCLC for the first time, with a 12-month PFS rate of 73.5%Wallstreetcn·Dec 7, 2025 at 10:48 AM02615688506+4.40%
【New Stock Listing】BIOKIN (2615) subscription entry fee is 39,293 yuan, and 5 funds including the US-listed pharmaceutical company BMS are invested in the stocketnet·Nov 6, 2025 at 11:59 PM02615